Serina Therapeutics' 2025 net loss widens as R&D expenses jump

Serina Therapeutics

25/03/2026 20:43

Overview

U.S. biotechnology firm's full-year revenue more than doubled from last year, in line analyst expectations

Operating expenses and net loss increased, mainly due to higher R&D and administrative costs

Company initiated Phase 1b trial for SER-252 and secured up to $30 mln in new financing

Outlook

Company did not provide specific financial or operational guidance for 2026

Result Drivers

R&D SPENDING - Higher research and development expenses were driven by increased clinical activity for SER-252, more staff, consultant costs, and outsourced research services

ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher stock-based compensation for new hires and directors, and consulting for public company infrastructure and investor outreach

OTHER INCOME DECLINE - Other income decreased mainly due to a lower gain from changes in warrant liabilities and losses from the sale of a subsidiary

Company press release: ID:nGNX9lcyf2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Meet
$130,000
$130,000 (2 Analysts)
FY Net Income
-$19.22 mln
FY Income From Operations
-$24.02 mln
FY Operating Expenses
$24.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Serina Therapeutics Inc is $13.00, about 435% above its March 24 closing price of $2.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)